Patient Counseling

Here are topics to discuss with your patients before vaccinating with SHINGRIX, including potential benefits and risks of immunization.    

Icon: What to Expect

What to Expect

Inform patients that they may experience adverse reactions after receiving SHINGRIX. In clinical trials, the most common adverse reactions observed were pain, redness, and swelling at the injection site, myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms.1

Icon: 2-Dose Series

2-Dose Series

Explain to patients that the efficacy results of SHINGRIX were demonstrated in clinical trials when administered as a 2-dose series. That is why it is important that your patients receive both doses of SHINGRIX.1

To help ensure series completion, encourage your patients to schedule their second dose for anytime between 2 and 6 months after their first dose.1

Icon: Flu Vaccination

Vaccinating for Flu?

Flu vaccination is a great time for a shingles conversation. When giving a flu vaccine to patients 50 years and older, don’t miss the opportunity to discuss SHINGRIX.*,

*In an open-label clinical study, subjects 50 years and older received 1 dose each of SHINGRIX and FLUARIX QUADRIVALENT (Influenza Vaccine) (QIV) at Month 0 and 1 dose of SHINGRIX at Month 2 (n=413), or 1 dose of QIV at Month 0 and 1 dose of SHINGRIX at Months 2 and 4 (n=415). There was no evidence for interference in the immune response to any of the antigens contained in SHINGRIX or the coadministered vaccine.1

SHINGRIX has not been studied with other influenza vaccines, including those that have an adjuvant component.

Icon: Topics to Discuss

More Topics to Discuss

Shingles Disease Risk

99.5% of adults aged ≥50 years are infected with the varicella zoster virus.2,3 In 1 out of 3 people the virus reactivates and causes shingles in their lifetime.3


SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).


SHINGRIX delivered >90% efficacy against shingles in patients ≥50 years of age.1,


In clinical trials with SHINGRIX, the most common solicited local and general adverse reactions were pain, redness, and swelling at the injection site, myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms.1 Please see the Safety Profile section for more information.

Data from the phase 3 ZOE-50 (≥50 years of age) trial (median follow-up period 3.1 years) and pooled data in individuals ≥70 years of age from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346, respectively). These populations represented the modified Total Vaccinated Cohort, defined as patients who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose.1,4 See study designs on the Efficacy page for details.

You may also be interested in:

See how you and your staff can reconstitute SHINGRIX in 4 steps. Vaccinate confidently.

See what CDC says about SHINGRIX.

Review profiles to see the types of potential patients for vaccination.

CDC=Centers for Disease Control and Prevention.